Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa.
Saved in:
| Title: | Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa. |
|---|---|
| Authors: | Burvenich IJG; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Melbourne, Victoria, 3084, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Goh YW; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Melbourne, Victoria, 3084, Australia., Guo N; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Melbourne, Victoria, 3084, Australia., Gan HK; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Melbourne, Victoria, 3084, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Rigopoulos A; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Melbourne, Victoria, 3084, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Cao D; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Melbourne, Victoria, 3084, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Liu Z; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Melbourne, Victoria, 3084, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Ackermann U; School of Cancer Medicine, La Trobe University, Melbourne, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; Department of Medicine, University of Melbourne, Melbourne, Australia., Wichmann CW; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Melbourne, Victoria, 3084, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., McDonald AF; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Melbourne, Victoria, 3084, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Huynh N; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Melbourne, Victoria, 3084, Australia., O'Keefe GJ; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; Department of Medicine, University of Melbourne, Melbourne, Australia., Gong SJ; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.; School of Engineering and Mathematical Sciences, La Trobe University, Melbourne, Australia., Scott FE; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Melbourne, Victoria, 3084, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, Australia., Li L; EMD Serono Research & Development Institute, Inc., a business of Merck KGaA, Darmstadt, Germany, Billerica, MA, USA., Geng W; EMD Serono Research & Development Institute, Inc., a business of Merck KGaA, Darmstadt, Germany, Billerica, MA, USA., Zutshi A; EMD Serono Research & Development Institute, Inc., a business of Merck KGaA, Darmstadt, Germany, Billerica, MA, USA., Lan Y; EMD Serono Research & Development Institute, Inc., a business of Merck KGaA, Darmstadt, Germany, Billerica, MA, USA., Scott AM; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, 145 Studley Road, Heidelberg, Melbourne, Victoria, 3084, Australia. andrew.scott@onjcri.org.au.; School of Cancer Medicine, La Trobe University, Melbourne, Australia. andrew.scott@onjcri.org.au.; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia. andrew.scott@onjcri.org.au.; Department of Medicine, University of Melbourne, Melbourne, Australia. andrew.scott@onjcri.org.au. |
| Source: | European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2021 Sep; Vol. 48 (10), pp. 3075-3088. Date of Electronic Publication: 2021 Feb 19. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1619-7089 (Electronic) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
